Comparison of clinical outcomes between the depot gonadotrophin-releasing hormone agonist protocol and gonadotrophin-releasing hormone antagonist protocol in normal ovarian responders

Gonadotrophin-releasing hormone.

Analogues of gonadotrophin releasing hormone.

Comparing gonadotrophin-releasing hormone agonists or gonadotrophin-releasing hormone antagonists in poor responder in IVF

Objective: The use of GnRH antagonist versus GnRH agonist in poor responder for patient undergoing ovarian hyperstimulation and in vitro-fertilization was compared. Materials and Methods: In this study, 23 patients underwent ovarian hyperstimulation with recombinant FSH followed by the use of GnRH antagonist (Cetrorelix) 0.25mg during the late Follicular Phase. These patients were compared to 2...

Pulsatile gonadotrophin secretion in women with polycystic ovary syndrome after gonadotrophin-releasing hormone agonist treatment.

In polycystic ovary syndrome (PCOS), increased luteinizing hormone (LH) pulse frequency has been attributed to either the hypothalamic gonadotrophin-releasing hormone (GnRH) pulse generator or ovarian oestrogen feedback. To address this issue, a detailed examination of pulsatile LH secretion was undertaken during recovery from GnRH agonist (GnRHa) suppression. Each of six women with PCOS and si...

Human chorionic gonadotrophin luteal support overcomes luteal phase inadequacy after gonadotrophin-releasing hormone agonist-induced ovulation in gonadotrophin-stimulated cycles.

Gonadotrophin-releasing hormone agonist (GnRHa)-induced ovulation after gonadotrophin ovarian stimulation is used to prevent ovarian hyperstimulation syndrome and multiple pregnancy in polyfollicular cycles. However, one of the major problems to be resolved is corpus luteum function after follicular maturation and ovulation by mid-cycle GnRHa administration. The present report investigated the ...